Incyte and Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Wall Street closes down sharply after Fed holds rates unchanged
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- Grant Thornton Advisors to buy CBIZ in $5 billion deal, expand US accounting reach
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
Incyte (INCY) Europe Granted Exclusive Iclusig Development, Commercialization Rights in EU, Additional Countries (ARIA)
June 1, 2016 4:13 PM EDTIncyte (NASDAQ: INCY) disclosed the following on Wednesday:
Item 1.01 Entry Into a Material Definitive Agreement.
On June 1, 2016, an Amended and Restated Buy-in License Agreement was entered into by ARIAD Pharmaceuticals, Inc. (ARIAD), ARIAD Pharmaceuticals (Europe) S.a.r.l. (ARIAD Europe), and Incyte Corporation (Incyte), as guarantor (the License Agreement). ARIAD Europe is one of the entities that became owned by Incyte Europe S.Ã .r.l. (Incyte Europe), a wholly-owned subsidiary of Incyte, upon the closing of the Acquisition described under Item 2.01 below. ARIAD Europe and Incyte Europe are collectively referred to in the remainder of... More
